Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 481

1.

Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine.

Prosser LA, Ray GT, O'Brien M, Kleinman K, Santoli J, Lieu TA.

Pediatrics. 2004 Feb;113(2):283-90.

PMID:
14754939
[PubMed - indexed for MEDLINE]
2.

The cost-effectiveness of pneumococcal conjugate vaccination in Australia.

Butler JR, McIntyre P, MacIntyre CR, Gilmour R, Howarth AL, Sander B.

Vaccine. 2004 Mar 12;22(9-10):1138-49.

PMID:
15003641
[PubMed - indexed for MEDLINE]
3.

Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland.

Ess SM, Schaad UB, Gervaix A, Pinösch S, Szucs TD.

Vaccine. 2003 Jul 4;21(23):3273-81.

PMID:
12804858
[PubMed - indexed for MEDLINE]
4.

New vaccines against otitis media: projected benefits and cost-effectiveness.

O'Brien MA, Prosser LA, Paradise JL, Ray GT, Kulldorff M, Kurs-Lasky M, Hinrichsen VL, Mehta J, Colborn DK, Lieu TA.

Pediatrics. 2009 Jun;123(6):1452-63. doi: 10.1542/peds.2008-1482.

PMID:
19482754
[PubMed - indexed for MEDLINE]
Free Article
5.

Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands.

Bos JM, Rümke H, Welte R, Postma MJ.

Clin Ther. 2003 Oct;25(10):2614-30.

PMID:
14667962
[PubMed - indexed for MEDLINE]
6.

Community and patient values for preventing herpes zoster.

Lieu TA, Ortega-Sanchez I, Ray GT, Rusinak D, Yih WK, Choo PW, Shui I, Kleinman K, Harpaz R, Prosser LA.

Pharmacoeconomics. 2008;26(3):235-49.

PMID:
18282017
[PubMed - indexed for MEDLINE]
7.

Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.

Bergman A, Hjelmgren J, Ortqvist A, Wisløff T, Kristiansen IS, Högberg LD, Persson KM, Persson U.

Scand J Infect Dis. 2008;40(9):721-9. doi: 10.1080/00365540802014872.

PMID:
18712627
[PubMed - indexed for MEDLINE]
8.

Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster.

Lieu TA, Ray GT, Ortega-Sanchez IR, Kleinman K, Rusinak D, Prosser LA.

Pharmacoeconomics. 2009;27(12):1005-16. doi: 10.2165/11314000-000000000-00000.

PMID:
19908925
[PubMed - indexed for MEDLINE]
9.

Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model.

De Wals P, Black S, Borrow R, Pearce D.

Clin Ther. 2009 Oct;31(10):2152-69. doi: 10.1016/j.clinthera.2009.10.014.

PMID:
19922887
[PubMed - indexed for MEDLINE]
10.

Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States.

Ray GT, Pelton SI, Klugman KP, Strutton DR, Moore MR.

Vaccine. 2009 Nov 5;27(47):6483-94. doi: 10.1016/j.vaccine.2009.08.045. Epub 2009 Aug 29.

PMID:
19720366
[PubMed - indexed for MEDLINE]
11.

The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine.

Silfverdal SA, Berg S, Hemlin C, Jokinen I.

Vaccine. 2009 Mar 4;27(10):1601-8. doi: 10.1016/j.vaccine.2008.12.033. Epub 2009 Jan 13.

PMID:
19146905
[PubMed - indexed for MEDLINE]
12.

Economic evaluation of universal infant vaccination with 7vPCV in Hong Kong.

Lee KK, Rinaldi F, Chan MK, Chan ST, So TM, Hon EK, Lee VW.

Value Health. 2009 Nov-Dec;12 Suppl 3:S42-8. doi: 10.1111/j.1524-4733.2009.00626.x.

PMID:
20586981
[PubMed - indexed for MEDLINE]
13.

Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.

Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, Kristiansen IS.

Vaccine. 2006 Jul 17;24(29-30):5690-9. Epub 2006 May 5.

PMID:
16735083
[PubMed - indexed for MEDLINE]
14.

Economic evaluation of second generation pneumococcal conjugate vaccines in Norway.

Robberstad B, Frostad CR, Akselsen PE, Kværner KJ, Berstad AK.

Vaccine. 2011 Nov 3;29(47):8564-74. doi: 10.1016/j.vaccine.2011.09.025. Epub 2011 Sep 21.

PMID:
21945264
[PubMed - indexed for MEDLINE]
15.

Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.

Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, Shepard DS.

Vaccine. 2011 Sep 2;29(38):6686-94. doi: 10.1016/j.vaccine.2011.06.091. Epub 2011 Jul 13.

PMID:
21745516
[PubMed - indexed for MEDLINE]
16.

Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine.

Stoecker C, Hampton LM, Link-Gelles R, Messonnier ML, Zhou F, Moore MR.

Pediatrics. 2013 Aug;132(2):e324-32. doi: 10.1542/peds.2012-3350. Epub 2013 Jul 1.

PMID:
23821695
[PubMed - indexed for MEDLINE]
Free Article
17.

Childhood vaccination against pneumococcal otitis media and pneumonia: an analysis of benefits and costs.

Weycker D, Richardson E, Oster G.

Am J Manag Care. 2000 Jul;6(10 Suppl):S526-35.

PMID:
11183904
[PubMed - indexed for MEDLINE]
Free Article
18.

Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain).

Navas E, Salleras L, Gisbert R, Domínguez A, Timoner E, Ibáñez D, Prat A.

Vaccine. 2005 Mar 18;23(17-18):2342-8.

PMID:
15755625
[PubMed - indexed for MEDLINE]
19.

Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review.

Boonacker CW, Broos PH, Sanders EA, Schilder AG, Rovers MM.

Pharmacoeconomics. 2011 Mar;29(3):199-211. doi: 10.2165/11584930-000000000-00000. Review.

PMID:
21250759
[PubMed - indexed for MEDLINE]
20.

Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.

Bos JM, Rümke HC, Welte R, Spanjaard L, van Alphen L, Postma MJ.

Pharmacoeconomics. 2006;24(2):141-53.

PMID:
16460135
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk